Compare EIG & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | GLUE |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.9M | 1.1B |
| IPO Year | 2007 | 2021 |
| Metric | EIG | GLUE |
|---|---|---|
| Price | $43.66 | $21.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 285.6K | ★ 2.6M |
| Earning Date | 02-19-2026 | 03-19-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.58 | 0.25 |
| Revenue | ★ $904,800,000.00 | $181,538,000.00 |
| Revenue This Year | $3.75 | $84.02 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $16.87 | $91.51 |
| Revenue Growth | 1.69 | ★ 1112.27 |
| 52 Week Low | $35.73 | $3.50 |
| 52 Week High | $52.29 | $25.77 |
| Indicator | EIG | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 53.21 |
| Support Level | $43.01 | $22.05 |
| Resistance Level | $45.99 | $23.29 |
| Average True Range (ATR) | 0.94 | 1.41 |
| MACD | -0.24 | -0.32 |
| Stochastic Oscillator | 23.99 | 1.19 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.